clinical trial · NCT06295159
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 90
Melanoma Stage IIIMelanoma Stage IVAdvanced MelanomaMelanomaNivolumabNivolumab + RelatlimabIpilimumab
brief summary
The purpose of this study is to determine if neoadjuvant (treatment before surgery) immunotherapy treatment based on tumor biomarkers results in better participant outcomes. Immunotherapy is the treatment of disease by using a person's own immune system. This study is divided into 2 sub-studies/parts designated Part 1 and Part 2 that will enroll in sequence starting with Part 1 followed by Part 2.
started
May 17, 2024
primary completion
Nov 1, 2028
completion
Nov 1, 2028
last updated
Apr 1, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol